Literature DB >> 12504799

Down-regulation of deoxycytidine kinase in human leukemic cell lines resistant to cladribine and clofarabine and increased ribonucleotide reductase activity contributes to fludarabine resistance.

Emma Månsson1, Emma Flordal, Jan Liliemark, Tatiana Spasokoukotskaja, Howard Elford, Svetlana Lagercrantz, Staffan Eriksson, Freidoun Albertioni.   

Abstract

Mechanisms of acquired resistance to three purine analogues, 2-chloro-2'-deoxyadenosine (cladribine, CdA), 9-beta-D-arabinofuranosyl-2-fluoroadenine (fludarabine, Fara-A), and 2-chloro-2'-arabino-fluoro-2'-deoxyadenosine (clofarabine, CAFdA) were investigated in a human T-lymphoblastic leukemia cell line (CCRF-CEM). These analogues are pro-drugs and must be activated by deoxycytidine kinase (dCK). The CdA and CAFdA resistant cell lines exhibited increased resistance to the other nucleoside analogues activated by dCK. This was also the case for the Fara-A resistant cells, except that they were sensitive to CAFdA and guanosine analogues. The CdA and CAFdA resistant cells displayed a deficiency in dCK activity (to <5%) while the Fara-A resistant cells showed only a minor reduction of dCK activity (20% reduction). The activity of high K(m) 5'-nucleotidase (5'-NT) (cN-II) using IMP as substrate, was 2-fold elevated in the resistant cell lines. The amount of the small subunit R2 of ribonucleotide reductase (RR) was higher in the Fara-A resistant cells, which translated into a higher RR activity, while CdA and CAFdA cells had decreased activity compared to the parental cells. Expression of the recently identified RR subunit, p53R2 full-size protein, in CAFdA cells was low compared to parental cells, but a protein of lower molecular weight was detected in CdA and CAFdA cells. Co-incubation of Fara-A with the RR inhibitor 3,4-dihydroxybenzohydroxamic acid (didox) enhanced cytotoxicity in the Fara-A resistant cells by a factors of 20. Exposure of the cells to the nucleoside analogues studied here also caused structural and numerical instability of the chromosomes; the most profound changes were recorded for CAFdA cells, as demonstrated by SKY and CGH analysis. We conclude that down-regulation of dCK in cells resistant to CdA and CAFdA and increased activity of RR in cells resistant to Fara-A contribute to resistance.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12504799     DOI: 10.1016/s0006-2952(02)01484-3

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  18 in total

1.  Optimization and evaluation of electroporation delivery of siRNA in the human leukemic CEM cell line.

Authors:  Anna Fyrberg; Kourosh Lotfi
Journal:  Cytotechnology       Date:  2010-10-19       Impact factor: 2.058

2.  Resistance to 9-beta-D-arabinofuranosyl-2-fluoroadenine due to reduced incorporation into DNA from competition by excess deoxyadenosine triphosphate: implications for different sensitivities to nucleoside analogues.

Authors:  Nobuyuki Yoshio; Yasukazu Kawai; Hiroki Hori; Takanori Ueda
Journal:  Int J Hematol       Date:  2005-06       Impact factor: 2.490

3.  Is 3'-deoxy-3'-(18)F-fluorothymidine a better marker for tumour response than (18)F-fluorodeoxyglucose?

Authors:  Sven N Reske; Sandra Deisenhofer
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-07       Impact factor: 9.236

4.  Preclinical rationale for synergistic interaction of pemetrexed and cytotoxic nucleoside analogues.

Authors:  Tetsuya Oguri; Hiroaki Ozasa; Takehiro Uemura; Osamu Takakuwa; Eiji Kunii; Daishi Kasai; Hirotsugu Ohkubo; Mikinori Miyazaki; Ken Maeno; Shigeki Sato
Journal:  Oncol Lett       Date:  2012-06-26       Impact factor: 2.967

5.  The synergistic cytotoxicity of clofarabine, fludarabine and busulfan in AML cells involves ATM pathway activation and chromatin remodeling.

Authors:  Benigno C Valdez; Yang Li; David Murray; Richard E Champlin; Borje S Andersson
Journal:  Biochem Pharmacol       Date:  2010-10-08       Impact factor: 5.858

6.  AAML0523: a report from the Children's Oncology Group on the efficacy of clofarabine in combination with cytarabine in pediatric patients with recurrent acute myeloid leukemia.

Authors:  Todd M Cooper; Todd A Alonzo; Robert B Gerbing; John P Perentesis; James A Whitlock; Jeffrey W Taub; Terzah M Horton; Alan S Gamis; Soheil Meshinchi; Michael R Loken; Bassem I Razzouk
Journal:  Cancer       Date:  2014-04-25       Impact factor: 6.860

7.  Use of clofarabine for acute childhood leukemia.

Authors:  A Pession; R Masetti; K Kleinschmidt; A Martoni
Journal:  Biologics       Date:  2010-06-24

8.  Synergism between clofarabine and decitabine through p53R2: a pharmacodynamic drug-drug interaction modeling.

Authors:  Karen E Thudium; Sampa Ghoshal; Gerald J Fetterly; Jason P Den Haese; Adam R Karpf; Meir Wetzler
Journal:  Leuk Res       Date:  2012-08-09       Impact factor: 3.156

9.  Phase I/II trial of clofarabine and cytarabine in children with relapsed/refractory acute lymphoblastic leukemia (AAML0523): a report from the Children's Oncology Group.

Authors:  Todd M Cooper; Bassem I Razzouk; Robert Gerbing; Todd A Alonzo; Kathleen Adlard; Elizabeth Raetz; Alan S Gamis; John Perentesis; James A Whitlock
Journal:  Pediatr Blood Cancer       Date:  2013-01-17       Impact factor: 3.167

10.  Phase II study of clofarabine in pediatric patients with refractory or relapsed acute myeloid leukemia.

Authors:  Sima Jeha; Bassem Razzouk; Michael Rytting; Susan Rheingold; Edythe Albano; Richard Kadota; Lori Luchtman-Jones; Lisa Bomgaars; Paul Gaynon; Stewart Goldman; Kim Ritchey; Robert Arceci; Arnold Altman; Kimo Stine; Laurel Steinherz; Peter Steinherz
Journal:  J Clin Oncol       Date:  2009-08-03       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.